New drug may protect breast cancer patients from dangerous infection risk
NCT ID NCT07380646
First seen Feb 02, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests whether a drug called leucogen can prevent severe neutropenia (dangerously low white blood cell counts) in people with early-stage hormone receptor-positive, HER2-negative breast cancer who are taking ribociclib and hormone therapy. About 94 participants will receive leucogen alongside their standard treatment. The goal is to see if leucogen reduces the risk of serious infections and allows patients to stay on their cancer therapy without dose reductions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast surgery department
RECRUITINGHangzhou, Zhejiang, 310058, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.